NO872223L - Bakteriociner og preparater inneholdende disse for antivirusbehandling. - Google Patents
Bakteriociner og preparater inneholdende disse for antivirusbehandling.Info
- Publication number
- NO872223L NO872223L NO872223A NO872223A NO872223L NO 872223 L NO872223 L NO 872223L NO 872223 A NO872223 A NO 872223A NO 872223 A NO872223 A NO 872223A NO 872223 L NO872223 L NO 872223L
- Authority
- NO
- Norway
- Prior art keywords
- cells
- bacteriocin
- virus
- infected
- cell
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 12
- 230000002155 anti-virotic effect Effects 0.000 title description 2
- 108010062877 Bacteriocins Proteins 0.000 claims description 97
- 210000004027 cell Anatomy 0.000 claims description 70
- 210000004698 lymphocyte Anatomy 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 19
- 108010073254 Colicins Proteins 0.000 claims description 17
- 230000012010 growth Effects 0.000 claims description 17
- 210000004962 mammalian cell Anatomy 0.000 claims description 16
- 230000003211 malignant effect Effects 0.000 claims description 15
- 241000700605 Viruses Species 0.000 claims description 12
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 11
- 108010025955 Pyocins Proteins 0.000 claims description 8
- 230000005764 inhibitory process Effects 0.000 claims description 8
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 5
- 230000010261 cell growth Effects 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 238000000684 flow cytometry Methods 0.000 claims description 4
- 201000006747 infectious mononucleosis Diseases 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 230000030833 cell death Effects 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 230000003993 interaction Effects 0.000 claims description 3
- 231100000518 lethal Toxicity 0.000 claims description 3
- 230000001665 lethal effect Effects 0.000 claims description 3
- 210000000265 leukocyte Anatomy 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 2
- 230000002147 killing effect Effects 0.000 claims description 2
- 238000005259 measurement Methods 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000007900 aqueous suspension Substances 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000002953 phosphate buffered saline Substances 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 239000003656 tris buffered saline Substances 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 9
- 229940104230 thymidine Drugs 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 208000036142 Viral infection Diseases 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000009385 viral infection Effects 0.000 description 7
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical group C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
- 235000011130 ammonium sulphate Nutrition 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 231100000590 oncogenic Toxicity 0.000 description 3
- 230000002246 oncogenic effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 239000001166 ammonium sulphate Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000012997 ficoll-paque Substances 0.000 description 2
- 239000012847 fine chemical Substances 0.000 description 2
- 230000007773 growth pattern Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 231100000588 tumorigenic Toxicity 0.000 description 2
- 230000000381 tumorigenic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 208000033766 Prolymphocytic Leukemia Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- QPADNTZLUBYNEN-UHFFFAOYSA-N etallobarbital Chemical compound C=CCC1(CC)C(=O)NC(=O)NC1=O QPADNTZLUBYNEN-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000006512 mast cell neoplasm Diseases 0.000 description 1
- 208000006971 mastocytoma Diseases 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 210000002325 somatostatin-secreting cell Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 108010054967 vibriocin Proteins 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- General Physics & Mathematics (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Physiology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- AIDS & HIV (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86825086A | 1986-05-28 | 1986-05-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO872223D0 NO872223D0 (no) | 1987-05-27 |
| NO872223L true NO872223L (no) | 1987-11-30 |
Family
ID=25351316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO872223A NO872223L (no) | 1986-05-28 | 1987-05-27 | Bakteriociner og preparater inneholdende disse for antivirusbehandling. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0247873A3 (xx) |
| JP (1) | JPS6379837A (xx) |
| AU (1) | AU7360387A (xx) |
| DK (1) | DK273087A (xx) |
| FI (1) | FI872363A (xx) |
| IL (1) | IL82627A0 (xx) |
| MC (1) | MC1822A1 (xx) |
| NO (1) | NO872223L (xx) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63290824A (ja) * | 1987-05-22 | 1988-11-28 | Sumitomo Chem Co Ltd | ウイルス感染症治療剤 |
| IL88480A0 (en) * | 1987-11-27 | 1989-06-30 | Univ Toronto | Proteinaceous compositions |
| CN1314806C (zh) * | 2005-01-14 | 2007-05-09 | 四川大学 | 小型化抗eb病毒肿瘤多肽及其应用与制备方法 |
| AU2021248774A1 (en) * | 2020-04-03 | 2022-11-03 | Blis Technologies Limited | Antiviral treatment comprising blis containing probiotic products |
-
1987
- 1987-05-22 IL IL82627A patent/IL82627A0/xx unknown
- 1987-05-27 NO NO872223A patent/NO872223L/no unknown
- 1987-05-27 FI FI872363A patent/FI872363A/fi not_active IP Right Cessation
- 1987-05-27 DK DK273087A patent/DK273087A/da not_active Application Discontinuation
- 1987-05-27 MC MC871890A patent/MC1822A1/xx unknown
- 1987-05-28 JP JP62130040A patent/JPS6379837A/ja active Pending
- 1987-05-28 AU AU73603/87A patent/AU7360387A/en not_active Abandoned
- 1987-05-28 EP EP87304731A patent/EP0247873A3/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP0247873A2 (en) | 1987-12-02 |
| MC1822A1 (fr) | 1988-03-18 |
| FI872363A (fi) | 1987-11-29 |
| DK273087A (da) | 1987-11-29 |
| DK273087D0 (da) | 1987-05-27 |
| EP0247873A3 (en) | 1988-10-19 |
| NO872223D0 (no) | 1987-05-27 |
| IL82627A0 (en) | 1987-11-30 |
| FI872363A0 (fi) | 1987-05-27 |
| JPS6379837A (ja) | 1988-04-09 |
| AU7360387A (en) | 1987-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sixbey et al. | Detection of a second widespread strain of Epstein-Barr virus | |
| Pfefferkorn et al. | Interferon-γ suppresses the growth of Toxoplasma gondii in human fibroblasts through starvation for tryptophan | |
| Bruckner | Amebiasis | |
| JP2770877B2 (ja) | ヘモフィラス・インフルエンザワクチン | |
| Van Der Veen et al. | Relationship of adenovirus to lymphocytes in naturally infected human tonsils and adenoids | |
| De Sena et al. | Partial purification and characterization of RTG-2 fish cell interferon | |
| Lotfollahi et al. | Prevalence and antimicrobial resistance profiles of Listeria monocytogenes in spontaneous abortions in humans | |
| Burchard et al. | Entamoeba histolytica: virulence potential and sensitivity to metronidazole and emetine of four isolates possessing nonpathogenic zymodemes | |
| Grabow et al. | Microcystis aeruginosa toxin: cell culture toxicity, hemolysis, and mutagenicity assays | |
| Grotendorst et al. | Complement effects on the infectivity of Plasmodium gallinaceum to Aedes aegypti mosquitoes. I. Resistance of zygotes to the alternative pathway of complement. | |
| Leirisalo et al. | Chemotaxis in yersinia arthritis HLA‐B27 positive neutrophils show high stimulated motility in vitro | |
| Ichinohe et al. | First isolation of Yersinia enterocolitica serotype O: 8 in Japan | |
| Kolman et al. | Comparison of the BACTEC and lysis concentration methods for recovery of Brucella species from clinical specimens | |
| US4861754A (en) | Bacteriocins and compositions thereof in anti-viral treatment | |
| Lam et al. | Newcastle disease virus-induced functional impairments and biochemical changes in chicken heterophils | |
| NO872223L (no) | Bakteriociner og preparater inneholdende disse for antivirusbehandling. | |
| Arimitsu et al. | Characterization of protective antibodies produced in mice infected with Borrelia duttonii | |
| Casleton et al. | Recovery and viability of Orientia tsutsugamwhi from packed red cells and the danger of acquiring scrub typhus from blood transfusion | |
| Duncan et al. | Production of Staphylococcal Alpha Toxin I. Relationship Between Cell Growth and Toxin Formation | |
| Petersen et al. | Francisella and Brucella | |
| Yanni et al. | Virological, molecular and immuno-biochemical studies of lumpy skin disease in naturally infected cattle | |
| Colón et al. | Mode of action of an inhibitor from agar on growth and hemagglutination of group A arboviruses | |
| Tilahun et al. | Sensitivity and Specificity of the Indirect Fluorescent Antibody Test in the Study of Four Murine Coccidia 1 | |
| Tsuchiya | Further studies on the cultivation of Endameba histolytica and a complement fixation test for amebiasis | |
| Kalf et al. | The isolation of deoxyribonucleic acid from lamb heart mitochondria |